Treatment benefits and outcome determinants in (neo)adjuvant trials
Treatment benefits and outcome determinants in (
Treatment benefits and outcome determinants in (
Preface – ESMO Solid Tumors 2022 © privat - Jaime R
Preface – ESMO Lung Cancer 2022 © ElainePerks2013 -
ESMO IO 2021 - David McDermott David McDermott de
ESMO IO 2021 - Mark G. Kris Mark G. Kris outlines
Established and novel chemo-free combinations in
Immune checkpoint blockade combined with chemoth
Preface © Andrea Enderlein Prof. Wolf H. Frid
DUBLIN-3:较后治疗线中的微管结合剂普那布林(plinabulin) 处于第二或第
ATALANTE-1:IO失败后的抗癌疫苗接种 OSE-2101是一种抗癌疫苗,具有仅限